1.
From the 27MAR14 ASX Announcement "Final Data Confirms Successful Phase I/IIa Clinical Trial for PAT-SM6", paragraph 6:
"These data compare favorably with another antibody (Elotuzumab)..."
1.1
What happened with Elotuzumab ($710M):
"Bristol-Myers Squibb is paying $30 million upfront in a licensing deal....And it will pay up to $680 million more if the Phase I cancer therapy hits all of its development and sales milestones."
http://www.fiercebiotech.com/story/bms-inks-710m-development-deal-pdl/2008-08-20
1.3
PAB's current market cap ~$30M.
pab research summary #2
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.6¢ |
Change
-0.001(14.3%) |
Mkt cap ! $12.34M | |||
| Open | High | Low | Value | Volume |
| 0.6¢ | 0.6¢ | 0.6¢ | $1.953K | 325.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 4291214 | 0.6¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.7¢ | 500160 | 1 |
View Market Depth
| Last trade - 11.14am 06/09/2024 (20 minute delay) ? |
| PAB (ASX) Chart |